Hillel Yaffe medical center
Hadera, 38100, Israel
NCT Number: NCT06643052
Early neonatal sepsis requires rapid and efficient intervention to prevent morbidity and mortality. Management of such a case includes invasive blood examinations, elongation of maternal and neonatal length of stay, and empiric antibiotic therapy. These actions has major side effects. On 2017, Kaiser-Permanente started using a calculator that weighs the chances for early onset neonatal sepsis, and states the best investigation and follow-up regimn for the specific newborn infant. Eversince, policy of managing neonatal suspected early onset sepsis has chaged globally, including in Israel. Current knowledge regarding the local outcome since the use of the calculatir is scarce.
The goal of the study is to evaluate the change in management of suspected neonatal early onset sepsis, including its economic value, between periods before and after assimilation of the calculator in Hillel Yaffe nedica l center.
Trial opening soon.
Get NotifiedUp to 7 day
All sexes
Observational
Hadera, 38100, Israel
Early neonatal sepsis requires rapid and efficient intervention to prevent morbidity and mortality. Management of such a case includes invasive blood examinations, elongation of maternal and neonatal length of stay, and empiric antibiotic therapy. These actions has major side effects. On 2017, Kaiser-Permanente started using a calculator that weighs the chances for early onset neonatal sepsis, and states the best investigation and follow-up regimn for the specific newborn infant. Eversince, policy of managing neonatal suspected early onset sepsis has chaged globally, including in Israel. Current knowledge regarding the local outcome since the use of the calculatir is scarce.
The goal of the study is to evaluate the change in management of suspected neonatal early onset sepsis, including its economic value, between periods before and after assimilation of the calculator in Hillel Yaffe nedical center.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
No intervention
Time frame: during first week of life
Total count of negative blood cultures out of all blood cultures in all patients in group
Time frame: during first week of life
Total count of positive blood cultures in all patients in group
Time frame: during first week of life
Total cost of Blood cultures + Blood counts + Antibiotic therpy in all patients in group
Contact information is provided by the study sponsor or research team.
Hillel Yaffe Medical Center
Other Gov
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07670624
Biomarker Discovery, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Wroclaw, Poland
View Trial DetailsNCT07663084
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Infant, Newborn, Diseases
View Trial DetailsNCT07585188
CLABSI - Central Line Associated Bloodstream Infection, CRBSI - Catheter Related Bloodstream Infection
Turin, Italy
View Trial DetailsNCT07572916
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Infant, Newborn, Diseases
Asyut, Egypt
View Trial Details